Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in Neuro-2A cells - An involvement of protein kinases

Neuropsychopharmacology

Volumn 31, Issue 4, 2006, Pages 853-865

  Basta Kaim, Agnieszka ^a   Budziszewska, Bogusława ^a   Jaworska Feil, Lucylla ^a   Tetich, Magdalena ^a   Kubera, Marta ^a   Leśkiewicz, Monika ^a   Otczyk, Magdalena ^a   Lasoń, Władysław ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antipsychotic drugs; Differentiated Neuro 2A cells; Forskolin; Human CRH gene; Phosphatidylinositol 3 kinase Akt pathway; Protein kinase C

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CHLORAMPHENICOL ACETYLTRANSFERASE; CHLORPROMAZINE; CLOZAPINE; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FORSKOLIN; GLYCOGEN SYNTHASE KINASE 3BETA; HALOPERIDOL; NEUROLEPTIC AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROMAZINE; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C ACTIVATOR; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; WORTMANNIN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; GENE ACTIVITY; GENE CONTROL; GENE REPRESSION; GENETIC TRANSFECTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MOUSE; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; WESTERN BLOTTING;

ANTIPSYCHOTIC AGENTS; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; NEURAL INHIBITION; NEURONS; PROMOTER REGIONS (GENETICS); PROTEIN KINASES; TRANSFECTION;

EID: 33645020526     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300911     Document Type: Article

References (66)

1. Aimoto T, Kaida M, Numazaki K, Masuda Y, Murata T (1981). Development of tolerance to the stimulatory effect of neuroleptic butyrophenones on pituitary-adrenal activity in rats. J Pharmacobiodyn 4: 827-832.
2. Altamura AC, Boin F, Maes M (1999). HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment. Eur Neuropsychopharmacol 10: 1-4.
3. Austin MC, Rhodes JL, Lewis DA (1997). Differential distribution of corticotropin-releasing hormone immunoreactive axons in monoaminergic nuclei of the human brainstem. Neuropsychopharmacology 17: 326-341.
4. Basta-Kaim A, Budziszewska B, Jaworska-Feil L, Tetich M, Kubera M, Leśkiewicz M et al (2005). Inhibitory effect of imipramine on the human corticotropin-releasing-hormone gene promoter activity operates through a PI3-K/AKT mediated pathway. Neuropharmacology 49: 156-164.
5. Basta-Kaim A, Budziszewska B, Jaworska-Feil L, Tetich M, Leśkiewicz M, Kubera M et al (2002). Chlorpromazine inhibits the glucocorticoid receptor-mediated gene transcription in a calcium dependent manner. Neuropharmacology 43: 1035-1043.
6. Binda AV, Kabbani N, Lin R, Levenson R (2002). D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N. Mol Pharmacol 62: 507-513.
7. Bloch M, Gur E, Shalev A (1994). Chlorpromazine prophylaxis of steroid-induced psychosis. Gen Hosp Psychiatry 16: 42-44.
8. Budziszewska B, Jaworska-Feil L, Kajta M, Lasoñ W (2000). Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism. Brit J Pharmacol 130: 1385-1393.
9. Budziszewska B, Jaworska-Feil L, Tetich M, Basta-Kaim A, Kubera M, Leśkiewicz M et al (2002). Effect of antidepressant drugs on the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells. Pol J Pharmacol 54: 711-716.
10. Budziszewska B, Jaworska-Feil L, Tetich M, Basta-Kaim A, Kubera M, Leśkiewicz M et al (2004). Regulation of the human corticotropin- releasing-hormone gene promoter activity by antidepressant drugs in Neuro-2A and AtT-20 cells. Neuropsychopharmacology 29: 785-794.
11. Chalecka-Franaszek E, Chuang DM (1999). Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 96: 8745-8750.
12. Chan MY, Holmes WN (1978). The effect of some centrally active drugs on corticosterone secretion and metabolism in rats. Clin Exp Pharmacol Physiol 5: 641-647.
13. Chatterjee D, Chakraborty M, Anderson GM (1992). Differentiation of Neuro-2a neuroblastoma cells by an antibody to GM3 ganglioside. Brain Res 583: 31-44.
14. De Sarno P, Li X, Jope RS (2002). Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43: 1158-1164.
15. Dirks A, Groenink L, Schipholt MI, van der Gugten J, Hijzen TH, Geyer MA et al (2002). Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry 51: 583-590.
16. Donati RJ, Thukral C, Rasenick MM (2001). Chronic treatment of C6 glioma cells with antidepressant drugs results in a redistribution of Gsα. Mol Pharmacol 59: 1426-1432.
17. Durany N, Thome J (2004). Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry 19: 326-337.
18. Dwivedi Y, Pandey GN (1999). Effects of treatment with haloperidol, chlorpromazine, and clozapine on protein kinase C (PKC) and phosphoinositide- specific phospholipase C (PI-PLC) activity and on mRNA and protein expression of PKC and PLC isozymes in rat brain. J Pharmacol Exp Ther 291: 688-704.
19. Dwivedi Y, Rizavi HS, Pandey GN (2002). Differential effects of haloperidol and clozapine on [3H]cAMP binding, protein kinase A (PKA) activity, and mRNA and protein expression of selective regulatory and catalytic subunit isoforms of PKA in rat brain. J Pharmacol Exp Ther 301: 197-209.
20. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004). Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat Genet 36: 131-137.
21. Fiol CJ, Williams JS, Chou CH, Wang QM, Roach PJ, Andrisani OM (1994). A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J Biol Chem 269: 32187-32193.
22. Forman SD, Bissette G, Yao J, Nemeroff CB, van Kammen DP (1994). Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia. Schizophr Res 12: 43-51.
23. Guardiola-Diaz HM, Boswell C, Seasholtz AF (1994). The cAMP-responsive element in the corticotropin-releasing hormone gene mediates transcriptional regulation by depolarization. J Biol Chem 269: 14784-14791.
24. Gudelsky GA, Berry SA, Meltzer HY (1989a). Actions of typical and atypical antipsychotics on tuberoinfundibular dopamine neurons. Psychopharmacol Bull 25: 377-382.
25. Gudelsky GA, Nash JF (1992). Neuroendocrinological and neurochemical effects of sigma ligands. Neuropharmacology 31: 157-162.
26. Gudelsky GA, Nash JF, Berry SA, Meltzer HY (1989b). Basic biology of clozapine: electrophysiological and neuroendocrinological studies. Psychopharmacology (Berl) 99(Suppl): S13-S17.
27. Hung F, Chan MY (1981). The effect of long-term chlorpromazine and desipramine treatment on adrenal corticosterone, cyclic AMP, and cholesterol distribution in rats. Clin Exp Pharmacol Physiol 8: 567-574.
28. Kahn RS, Siever L, Davidson M, Greenwald C, Moore C (1993). Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology (Berl) 112(1 Suppl): S90-S94.
29. Karege F, Schwald M, El Kouaissi R (2004). Drug-induced decrease of protein kinase a activity reveals alteration in BDNF expression of bipolar affective disorder. Neuropsychopharmacology 29: 805-812.
30. Keim KL, Sigg EB (1977). Plasma corticosterone and brain catecholamines in stress: effect of psychotropic drugs. Pharmacol Biochem Behav 6: 79-85.
31. Klebe RJ, Ruddle FH (1969). Neuroblastoma: cell culture analysis of a differentiating stem cell system. J Cell Biol 43: 69.
32. Kozlovsky N, Belmaker RH, Agam G (2002). GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol 12: 13-25.
33. Lai M, McCormick JA, Chapman KE, Kelly PAT, Seckl JR, Yau JLW (2003). Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture. Neuroscience 118: 975-984.
34. Lammers CH, Garcia-Borreguero D, Schmider J, Gotthard U, Dettling M, Holsboer F et al (1995). Combined dexamethasone/ corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol Psychiatry 38: 803-807.
35. Legradi G, Holzer D, Kapcala LP, Lechan RM (1997). Glucocorticoids inhibit stress-induced phosphorylation of CREB in corticotropin-releasing hormone neurons of the hypothalamic paraventricular nucleus. Neuroendocrinology 66: 86-97.
36. Ling MH, Perry PJ, Tsuang MT (1981). Side effects of corticosteroid therapy. Psychiatric aspects. Arch Gen Psychiatry 38: 471-477.
37. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
38. Lu XH, Bradley RJ, Dwyer DS (2004). Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res 1011: 58-68.
39. Marinelli M, Piazza PV, Deroche V, Maccari S, Le Moal M, Simon H (1994). Corticosterone circadian secretion differentially facilitates dopamine-mediated psychomotor effect of cocaine and morphine. J Neuroscience 14: 2724-2731.
40. Marinelli M, Rouge-Pont F, Deroche V, Barrot M, De Jesus-Oliveira C, Le Moal M et al (1997). Glucocorticoids and behavioral effects of psychostimulants. I: Locomotor response to cocaine depends on basal levels of glucocorticoids. J Pharmacol Exp Ther 281: 1392-1400.
41. McEwen BS, Magarinos AM (2001). Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders. Hum Psychopharmacol 16: S7-S19.
42. Meltzer HY (1995). Dopamine, serotonin and glucorticoids and the psychopathology of schizophrenia. In: Fog R, Gerlach J (eds). Schizophrenia. Alfred Bunsen Symposium 38, Munksgaard, Copenhagen. pp 74-91.
43. Monsma Jr FJ, Brassard DL, Sibley DR (1989). Identification and characterization of D1 and D2 dopamine receptors in cultured neuroblastoma and retinoblastoma clonal cell lines. Brain Res 492: 314-324.
44. Newcomer JW, Faustman WO, Whiteford HA, Moses Jr JA, Csernansky JG (1991). Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. Biol Psychiatry 29: 855-864.
45. Nikodemova M, Kasckow J, Liu H, Manganiello V, Aguilera G (2003). Cyclic adenosine 3′,5′-monophosphate regulation of corticotropin-releasing hormone promoter activity in AtT-20 cells and in a transformed hypothalamic cell line. Endocrinology 144: 1292-1300.
46. Ninan I, Jardemark KE, Liang X, Wang RY (2003). Calcium/calmodulin- dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells. Synapse 47: 285-294.
47. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH (1997). Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 52: 571-581.
48. Peruche B, Krieglstein J (1991). Neuroblastoma cells for testing neuroprotective drug effects. J Pharmacol Methods 26: 139-148.
49. Piazza PV, Rouge-Pont F, Deroche V, Maccari S, Simon H, Le Moal M (1996). Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc Natl Acad Sci USA 93: 8716-8720.
50. Post A, Holsboer F, Behl C (1998). Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants. J Neurosci 18: 8236-8246.
51. Pozzi L, Hakansson K, Usiello A, Borgkvist A, Lindskog M, Greengard P et al (2003). Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J Neurochem 86: 451-459.
52. Ratnakar P, Rao SP, Sriramarao P, Murthy PS (1995). Structure- antitubercular activity relationship of phenothiazine-type calmodulin antagonists. Int Clin Psychopharmacol 10: 39-43.
53. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH (2004). The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 74: 1999-2008.
54. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ (1998). Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 18: 790-798.
55. Seasholtz AF, Thompson RC, Douglass JO (1988). Identification of a cyclic adenosine monophosphate-responsive element in the rat corticotropin-releasing hormone gene. Mol Endocrinol 2: 1311-1319.
56. Smith CL, Wolford RG, O'Neill TB, Hager GL (2000). Characterization of transiently and constitutively expressed progesterone receptors: evidence for two functional states. Mol Endocrinol 14: 956-971.
57. Spengler D, Rupprecht R, Van LP, Holsboer F (1992). Identification and characterization of a 3′,5′-cyclic adenosine monophosphate- responsive element in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol 6: 1931-1941.
58. Sweep CG, Boersma CJ, Wiegant VM (1990). Effects of chronic treatment with haloperidol and bromocriptine on the processing of beta-endorphin to gamma- and alpha-endorphin in discrete regions of the rat pituitary gland and brain. Neuropharmacology 29: 61-68.
59. Tandon R, Mazzara C, DeQuardo J, Craig KA, Meador-Woodruff JH, Goldman R et al (1991). Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry 29: 953-964.
60. Tyson DR, Swarthout JT, Jefcoat SC, Partridge NC (2002). PTH induction of transcriptional activity of the cAMP response element-binding protein requires the serine 129 site and glycogen synthase kinase-3 activity, but not casein kinase II sites. Endocrinology 143: 674-682.
61. Vamvakopoulos NC, Chrousos GP (1994). Hormonal regulation of human corticotropin-releasing hormone gene expression: implications for the stress response and immune/inflammatory reaction. Endocrine Rev 15: 409-420.
62. Webster MJ, Knable MB, O'Grady J, Orthmann J, Weickert CS (2002). Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 7: 985-994.
63. Wik G, Wiesel FA, Eneroth P, Sedvall G, Astrom G (1986). Dexamethasone suppression test in schizophrenic patients before and during neuroleptic treatment. Acta Psychiat Scand 74: 161-167.
64. Yamamori E, Asai M, Yoshida M, Takano K, Itoi K, Oiso Y et al (2004). Calcium/calmodulin kinase IV pathway is involved in the transcriptional regulation of the corticotropin-releasing hormone gene promoter in neuronal cells. J Mol Endocrinol 33: 639-649.
65. Yang BH, Son H, Kim SH, Nam JH, Choi JH, Lee JS (2004). Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration. Psychiatry Clin Neurosci 58: 262-267.
66. Zhu D, Jiang X, Wu X, Tian F, Mearow K, Lipsky RH et al (2004). Inhibition of protein kinase C promotes neuronal survival in low potassium through an Akt-dependent pathway. Neurotox Res 6: 281-289.